• Posted on Monday, September 15, 2008
  • Bookmark and Share
  • email
  • |
  • print
  • |
  • rss

tool name

close
tool goes here

New psychotropic drugs no better than the old, study finds

email this story print this story jump to comments

A comparison of medications for severe mental illness shows that an old drug works just as well as new ones for teenagers, plus it doesn't cause the weight gain that has worried patients, parents and doctors, researchers at the University of North Carolina at Chapel Hill report today.

The study, the first to compare the two generations of schizophrenia drugs, could change the way doctors prescribe treatments for teens. The powerful new medications are increasingly prescribed for a variety of disorders, including aggression, hyperactivity, depression and autism.

A national study published in 2006 found that between 1993 and 2002, there was a sixfold increase in the number of doctor visits that resulted in young people getting prescriptions for antipsychotic medications.

And overwhelmingly, teenagers are prescribed the new drugs, which include Risperdal, Zyprexa, Seroquel, Geodon and Abilify.

Few of the drugs have been specifically approved by the Food and Drug Administration for children. But they are widely prescribed because doctors have perceived them as generally safe.

Read the full story at newsobserver.com.

  • Bookmark and Share
  • email
  • |
  • print
  • |
  • rss

tool name

close
tool goes here
JOIN THE DISCUSSION

We welcome comments. To post one, you must sign in using either your McClatchyDC login or your login for Facebook, Twitter or Disqus. Just click the appropriate box below.

Please keep your comment civil, short and to the point. Obscene, profane, abusive and off topic comments will be deleted. Repeat offenders will be blocked. If you find a comment abusive or inappropriate, please flag it for the moderator by placing your cursor on the comment, then clicking the "flag" link that appears. Thanks for your participation.

Stay Connected

Sign up for email newsletters RSS
Follow us on your iPhone Follow us on your Android device
Follow us on Facebook Follow us on Twitter Follow us using Google Currents